Press release
Premature Ejaculation Treatment Has Experienced Evident Progress Over the Last Two to Three Decades
Epelsiban, IX-01 and DA-8031 are among potential drugs undergoing clinical trials for the treatment of premature ejaculationPremature Ejaculation Market – Global Outlook and Forecast 2017–2022 is the latest report published by Arizton Advisory & Intelligence. The report not only includes the insights of the premature ejaculation treatment market but also provides a detailed analysis of the drug pipeline landscape.
View report: Premature Ejaculation Market – Global Outlook and Forecast 2017–2022
https://www.arizton.com/reports/healthcare-lifesciences/premature-ejaculation-market
The premature ejaculation treatment pipeline dynamics is relatively weak with considerably a few drug molecules undergoing clinical trial evaluation. A number of innovative pipeline drug molecules are being evaluated for safety and efficacy across the various stages of the clinical development.
The condition of PE was ambiguous in terms of disease definition, etiology, and targetable drug sites till recently. Inadequate knowledge about the disease, lack of evidence-based definition of premature ejaculation, and validated patient sexuality questionnaires, known as PROs can be presumed as a few of the factors, which hindered the invention of new drug molecules capable of treating the disease.
The advent of the use of topical anesthetic agents is considered as a key preliminary breakthrough for the management of premature ejaculation treatment. The initiation of administration has further strengthened effectiveness of disease management. Nonetheless, there is a significant unmet demand in the premature ejaculation market, says the analysts team at Arizton Advisory & Intelligence. The immediate need for the premature ejaculation treatment is invention of new on-demand rapid acting drugs, which can hold the potential to target multiple receptors and may form the foundation of more effective future on-demand medication with minimal or no associated adverse events.
Advances in scientific research have undisclosed new pathways of disease pathophysiology and etiology, which ultimately widen the drug target sites and led to innovative lead molecules for the premature ejaculation treatment and management. The implementation of evidence-based or proven assessment parameters for determination of efficacy and safety of investigational molecules is leading to the innovation of superior drugs. The proven assessment parameters and data evaluation end-points are also assisting in termination of clinical progress of ineffective drugs for the premature ejaculation treatment.
View report: Premature Ejaculation Market – Global Outlook and Forecast 2017 – 2022
https://www.arizton.com/reports/healthcare-lifesciences/premature-ejaculation-market
A few of the key drugs, which are currently holding the potential to be approved for treatment of PE are undergoing early stage clinical studies. These include selective oxytocin receptor antagonists – IX-01 and GSK557296, novel SSRI drug candidate DA-8031, and repurposed clomipramine.
Source: https://www.arizton.com/news/press-release/premature-ejaculation-treatment-has-experienced-evident-progress-over-the-last-two-to-three-decades
About Arizton Advisory & Intelligence
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Premature Ejaculation Treatment Has Experienced Evident Progress Over the Last Two to Three Decades here
News-ID: 804912 • Views: …
More Releases for Premature
Premature Labor (Tocolysis) Market Size, Share and Growth Report, 2034
Introduction
The premature labor tocolysis market addresses one of the most critical challenges in obstetrics-delaying preterm birth to improve neonatal survival and reduce complications. Tocolytic therapy involves the use of medications to suppress uterine contractions, giving physicians valuable time for administering antenatal corticosteroids or transferring patients to facilities equipped for high-risk deliveries.
The market is gaining momentum due to increasing preterm birth rates globally, better perinatal care infrastructure, and ongoing advancements in…
Premature Treatment Market Anticipates a Noteworthy CAGR of 9.9%
The premature treatment market addresses a prevalent and distressing sexual health concern that impacts a significant number of men globally. Premature (PE) is characterized by the consistent and uncontrollable that occurs shortly after or even before sexual penetration, leading to dissatisfaction and frustration for both partners. The market for premature treatment encompasses a variety of therapeutic approaches aimed at improving ejaculatory control, prolonging sexual activity, and enhancing overall sexual satisfaction.
Market…
Increasing Premature Births Boost Enteral Nutrition Market
The enteral nutrition market will touch USD 13,811.6 million, growing at a 6.2% compound annual growth rate, by 2030.
The growth of this industry is mainly because of the increasing elderly population, surging occurrence of malnutrition, and growing count of premature births, which results in rising ICU deaths.
Request for sample pages of this report: https://www.psmarketresearch.com/market-analysis/enteral-nutrition-market/report-sample
Moreover, the increasing incidence of chronic conditions like cancer, chronic liver disease, stroke, diabetes, multiple sclerosis, chronic…
Urbaser provides extra support to employees with premature babies
Environmental services company, Urbaser, has agreed to offer extra support for its UK staff who are the parents of premature babies by introducing the Smallest Things policy.
The Smallest Things campaign asks employers to provide parents of premature babies with extra leave, at full pay, to help them through what can be a very difficult time. Mothers and fathers of babies born at or before 37 weeks can have an extra…
Premature Ejacualtion Market - Global Outlook and Forecast to 2022
ReportsnReports.com adds "Premature Ejacualtion Market - Global Outlook and Forecast 2017 – 2022" report to its research store.
The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017-2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.
Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are…
Premature Ejaculation Treatment Market- Insights
Ejaculation means discharging of semen from the body. Premature ejaculation (PE) also known as rapid ejaculation, premature climax or early ejaculation is a condition in which the ejaculation happens earlier than a man or his partner would like during a sexual intercourse. The main sign of PE is incapability to delay ejaculation for more than one minute after penetration. Mainly PE can be classified in two types, namely lifelong (primary)…
